

thromboxane synthesis in the following manner: ADP < EP < AA. Our previous work¹¹ agrees with this, if in fact CO inhibits thromboxane synthesis, since CO inhibits platelet aggregation as follows: ADP < EP < AA.

Our in vitro experiments may, however, not be directly comparable to the in vivo situation possibly due to the synergistic actions of many aggregating agents with ADP²² since ADP release, although inhibited in the presence of CO and in smokers is not absent. Also important is that serotonin release by AA is unaffected. Rao and White's finding²³ that drug-induced defects in platelet prostaglandin synthesis may be compensated for by membrane modulation and receptor cooperativity also complicates the extrapolation of in vitro obtained data to in vivo situations.

The presence of deaggregating agents as well as the alteration

of platelet sensitivity towards them is another complication. Recently Pittilo et al.²⁴ have shown that prostacyclin production in vitro is decreased in smoking rats. Diminished prostacyclin formation has also been shown in umbilical arteries of babies born to smoking women²⁵. Our data showing that serotonin release is inhibited in smokers may support this, since serotonin can act as a coenzyme for prostaglandin biosynthesis²⁶. Recent data from other workers have suggested that smokers' platelets may be less sensitive to prostacyclin²⁷. Therefore, although platelet aggregation and the release reaction are generally decreased in the presence of CO and in smokers, they may not reflect the in vivo situation. Atherosclerosis in smokers probably occurs due to a combination of interacting factors for which no one in vitro experiment can give a clear understanding.

- 1 This work was supported by Veterans Administration Research Fund 8073-01.
- 2 Murphy, E.A., and Mustard, J.F., *Am. J. publ. Hlth* 56 (1966) 1061.
- 3 Dawber, T.R., Kannel, W.B., Revotski, N., Stokes, J., Kagan, A., and Gordon, T., *Am. J. publ. Hlth* 49 (1959) 1349.
- 4 Spain, D.M., and Bradess, V.A., *Chest* 58 (1970) 107.
- 5 Glynn, M.F., Mustard, J.F., Buchanan, M.R., and Murphy, E.A., *J. Assoc. med. Canad.* 95 (1966) 549.
- 6 Levine, P.H., *Circulation* 48 (1973) 619.
- 7 Grignani, G., Gamba, G., and Ascari, E., *Thromb. Haemost.* 37 (1977) 423.
- 8 Hughes, A., and Tonks, R.S., *J. Path. Bact.* 84 (1962) 379.
- 9 Jorgensen, L., Rowsell, H.C., Hovig, T., Glynn, M.F., and Mustard, J.F., *Lab. Invest.* 17 (1967) 616.
- 10 Jorgensen, L., Torstein, H., Rowsell, H.C., and Mustard, J.F., *Am. J. Path.* 61 (1980) 161.
- 11 Mansouri, A., and Perry, C.A., *Thromb. Haemost.* 48 (1982) 286.
- 12 Charo, I.F., Feinman, R.D., and Detwiler, T.C., *Nature* 269 (1977) 66.
- 13 Charo, I.F., Feinman, R.D., and Detwiler, T.C., *J. clin. Invest.* 60 (1977) 866.
- 14 Valdorf-Hansen, J.F., and Zucker, M.B., *Am. J. Physiol.* 220 (1971) 105.
- 15 Weiss, J.H., *Am. J. Med.* 43 (1967) 570.
- 16 Peterson, D.A., Gerrard, J.M., Rao, G.H.R., and White, J.G., *Prostaglandins Med.* 2 (1979) 97.
- 17 Cinti, D.L., and Feinstein, M.B., *Biochem. biophys. Res. Commun.* 73 (1976) 171.
- 18 Moroff, G., and Kosow, D.P., *Thromb. Res.* 23 (1981) 23.
- 19 Coburn, R.F., *Prev. Med.* 8 (1979) 310.
- 20 Maddox, I.S., *Biochim. biophys. Acta* 306 (1973) 74.
- 21 Siess, W., Roth, P., and Weber, P.C., *Thromb. Haemost.* 45 (1981) 204.
- 22 Packham, M.A., Guccione, M.A., Greenberg, J.P., Kinlough-Rathbone, R.L., and Mustard, J.F., *Blood* 50 (1977) 915.
- 23 Rao, G.H.R., and White, J.G., *Am. J. Hemat.* 11 (1981) 355.
- 24 Pittilo, R.M., Mackie, I.J., Rowles, P.M., Machin, S.J., and Woolf, N., *Thromb. Haemost.* 48 (1982) 173.
- 25 Dadak, C., Leithner, C., Sinzinger, H., and Silberbauer, K., *Lancet* 1 (1981) 94.
- 26 Sih, C., Takeguchi, C., and Foss, P., *J. Am. chem. Soc.* 92 (1970) 6670.
- 27 Sinzinger, H., Kaliman, J., Widhalm, K., Pachinger, O., and Probst, P., *Prostaglandins Med.* 7 (1981) 125.

0014-4754/84/050515-03\$1.50 + 0.20/0

© Birkhäuser Verlag Basel, 1984

Metabolic implications in the elevation of serum activity of intestinal alkaline phosphatase in chronic renal failure

J. Štěpán, T. Havránek, E. Jelínková, M. Straková, J. Škrha and V. Pacovský

3rd Department of Internal Medicine, and 2nd Department of Internal Medicine, Charles University Faculty of Medicine, U nemocnice 1, CS-12800 Praha (Czechoslovakia) and Centre of Biomathematics, Czechoslovak Academy of Sciences, Praha (Czechoslovakia), 27 June 1983

Summary. The activity of intestinal isoenzyme of serum alkaline phosphatase was evaluated in 21 non-dialyzed patients with advanced renal failure and in 52 patients on regular hemodialysis. In patients without hepatopathy, a significant inverse correlation was found between the enzyme activity and serum calcium levels. Hepatopathy was the most significant variable influencing the enzyme activity in patients on dialysis. Secondary hyperparathyroidism and a decreased rate in enzyme elimination should be assessed for the above-normal activities of intestinal ALP in serum in chronic renal failure.

Elevation in the serum activity of intestinal isoenzyme of alkaline phosphatase (EC 3.1.3.1) has been described in patients on regular hemodialysis¹⁻³. The present investigations were designed to determine the factors which influence the changes in the enzyme activity in chronic renal failure.

Patients and Methods. Measurements were made in 21 non-dialyzed patients with advanced renal failure (creatinine clearance mean \pm 2 SD range, 35 ml/min, and 13-85 ml/min, respectively) and in 52 patients on regular hemodialysis. No patients received phosphate binders, vitamin D or its derivatives, anti-convulsants or corticosteroids (except for the transplant patients and patients with an active hepatitis). In 37 patients (35 on dialysis), a chronic hepatopathy was documented by a pre-

vious history of acute hepatitis and serial evaluation of liver tests. The dialysis calcium concentration was 2.3 mmol/l. Nine patients had a previous history of a non-successful renal transplantation. The control group consisted of 40 adults without evidence of renal, hepatobiliary, or bone disease. Blood samples were drawn in the morning after a fasting period of approximately 8 h, in patients on dialysis before the dialysis. Informed consent was obtained from all the patients.

The activity of the intestinal, liver and bone isoenzyme of serum alkaline phosphatase (ALP) was determined with 4-nitrophenyl phosphate as substrate⁴. The total concentration of calcium in the serum was determined with methylthymol blue and

corrected for individual variations in serum albumin concentration⁵, inorganic phosphate in the serum was determined photometrically⁶. In all patients, determinations of the serum activity of alanine aminotransferase (EC 2.6.1.2), gamma-glutamyl transferase (EC 2.3.2.1, GMT) cholinesterase with butyryl thiocholine as substrate (EC 3.1.1.8), albumin, creatinine, and clearance of endogeneous creatinine, were performed. The serum immunoreactive parathyroid hormone (iPTH) was determined by radioimmunoassay, using Human Parathyroid Hormone PTH II and Human N-Terminal Parathyroid Hormone Kits (Immuno Nuclear Corp., MN, USA). The kits were kindly provided by DRG International, NJ, USA. Statistical analysis of the results was performed by commonly accepted methods using BMDP IV, 1R, 6R, 9R, 6M and 7M programs of the Health Science Computing Facility, University of California, Los Angeles, USA⁷.

Results. Mean values for the variables are shown in the table. The intestinal isoenzyme activity in patients without biochemical and clinical evidence of hepatopathy was most significantly influenced by serum calcium level (fig.). Accordingly, in these patients a significant positive correlation was found between serum iPTH and intestinal ALP activity (log intestinal ALP activity (log intestinal ALP = 0.21 + 0.72 log iPTH, $r = 0.61$, $n = 19$, $p < 0.01$).

The figure shows that the activity of the intestinal isoenzyme of serum ALP in 44% of the patients with hepatopathy fell out of the 95% confidence limits of the regression observed in patients without hepatopathy. No significant correlation was found between iPTH values and intestinal ALP activity in patients with hepatopathy. The multiple regression analysis showed that the activity of the intestinal ALP in serum of patients with hepatopathy was significantly influenced by blood group, liver ALP activity in serum and serum GMT activity.

Discussion. The results of the present study indicate that the liver functional state and the role of serum calcium should be considered as being involved not only in an increased entrance rate of the enzyme into the blood, but also in the removal of intestinal ALP from the circulation. In our patients who had

normal liver function tests and normal serum calcium level, a normal activity of intestinal ALP was found.

In contrast to the other organ-specific forms of ALP, the adult intestinal ALP is an asialoglycoprotein⁸. A damage to the hepatocyte plasma membrane is known to interfere with the hepatic uptake of circulating desialylated glycoproteins and lead to their accumulation in serum⁹, especially if the patients blood group is type O¹⁰. The binding activity of the asialoglycoprotein receptor of hepatocytes has been shown to depend on calcium ions¹¹. However, hypocalcemia and a consequent secondary hyperparathyroidism might lead to an increased rate of entrance of the enzyme into serum as well. Birge and Gilbert¹² identified an ALP in rat intestine that was stimulated by parathyroid hormone. An augmented catalytic efficiency of the intestinal ALP could also account for its increased activity¹³.

- 1 Walker, A.W., Clinica chim. Acta 55 (1974) 399.
- 2 De Broe, M.E., Bosteels, V., and Wieme, R.J., Lancet 1 (1974) 753.
- 3 Štěpán, J., and Pilařová, T., Lancet 1 (1975) 1188.
- 4 Štěpán, J., Volek, V., and Kolář, J., Clinica chim. Acta 69 (1976) 1.
- 5 Gindler, E., and King, J.D., Am. J. clin. Path. 58 (1972) 376.
- 6 Heinonen, J.K., and Lahti, R.J., Analyt. Biochem. 113 (1981) 313.
- 7 Dixon, W.J., BMDP Biomedical Computer Programs. University of California Press, Berkeley and Los Angeles 1976.
- 8 Meijer, D.K.F., Scholtens, H.B., and Hardonk, M.J., Pharm. Weekbl. Ned. 4 (1982) 57.
- 9 Marshall, J.S., and Williams, S., Biochim. biophys. Acta 543 (1978) 41.
- 10 Stolbach, L.L., Krant, M.J., Inglis, N.I., and Fishman, W.H., Gastroenterology 52 (1967) 819.
- 11 Blomhoff, R., Tolleshaug, H., and Berg, T., J. biol. Chem. 257 (1982) 7456.
- 12 Birge, S.J., and Gilbert, H.R., J. clin. Invest. 54 (1974) 710.
- 13 Lecchi, C., De Bastiani, G., and Zatti, M., Clinica chim. Acta 57 (1974) 171.

0014-4754/84/050517-02\$1.50 + 0.20/0

© Birkhäuser Verlag Basel, 1984

Instructions to Authors

Experientia is a monthly journal of natural sciences devoted to publishing articles which are interdisciplinary in character and which are of general scientific interest. Considered for publication will be hitherto unpublished papers that fall within one of four categories:

Reviews (one-man and multi-author reviews)

Full Papers (in-depth reports not exceeding 4–6 printed pages)

Mini-reviews (1–2 printed pages)

Short Communications (1–2 printed pages)

Papers reporting on work that is preliminary in nature, or wherein animal experiments have been conducted without the appropriate anesthesia, will not be accepted.

Manuscript (including all tables and figures) must be submitted in *triplicate* and must be in *English*. *Title pages* should bear the author's name and address (placed directly below the title), a brief *abstract* (of approximately 50 words for short communications) mentioning new results only, and a listing of *key words*. *Footnotes* must be avoided. *Tables*, and then *figures*, are to follow the body of the text and should be marked with self-explanatory captions and be identified with the author's name. All *data* should be expressed in units conforming to the *Système International* (SI). *Drawings* are to be on heavy bond paper and marked clearly in black. *Photographs* should be supplied as glossy positive prints. Please note that we use two different systems for citing references. 1. For *Review Articles* and *Full Papers*, references should be arranged alphabetically and be numbered. Within the text, literature should be referred to by number and, where indicated, by author. The references should contain full journal article titles and the first as well as the last page of the article cited. 2. For *Short Communications*, an abbreviated bibliography is requested and references should be listed chronologically. Please consult a current issue of *Experientia* or inquire at the editorial office for details on form.

Authors are requested to specify under which section heading they would wish their communication to appear:

1. Chemistry, Physics, Biomathematics
2. Physiology, Pathophysiology (animals)
3. Physiology, Pathophysiology (plants)
4. Biochemistry
5. Anatomy, Histology, Histochemistry
6. Pharmacology, Toxicology
7. Molecular Biology
8. Immunology
9. Cellular Biology
10. Genetics, Developmental Biology, Aging
11. Oncology
12. Endocrinology
13. Neurobiology, Behavior
14. Environment, Ecology
15. Experimental Pathology and Clinical Research
16. Microbiology
17. New Methods and Apparatus

All incoming manuscripts are acknowledged immediately. Authors will be notified of the editorial board's publishing decision once their manuscripts have been evaluated by a minimum of two field experts. Fifty reprints of papers accepted for publication will be sent to authors free of charge; additional reprints may be ordered. Manuscripts and all communications to the editors should be addressed to:

Experientia
Birkhäuser Verlag
P.O. Box 133
CH-4010 Basel/Switzerland
Tel. 061 23 18 10